Latest / Views and News with Clarence Ford / Groundbreaking Clinical Trial Launched to Advance Maternal Nutrition in South Africa
Transcript
- 0:00Speaker 1: In a city that never runs out of opinions, Kate
- 0:03Speaker 1: Talk is the place to hear them. More news, views, life,
- 0:09Speaker 1: It's all here. Kate Talk joined the conversation and now
- 0:15Speaker 1: we're going to be celebrating another very significant development. It's
- 0:18Speaker 1: a groundbreaking clinical trial was launched to advanced maternal nutrition
- 0:23Speaker 1: in South Africa. Verona vit Boy is my guest, a
- 0:28Speaker 1: country program manager for South Africa at Site and Life Foundation.
- 0:32Speaker 1: It's a global humanitarian nutrition foundation. It's dedicated to eliminating
- 0:36Speaker 1: malnutrition through science and evidence based interventions. Verona itself is
- 0:42Speaker 1: a very significant experience, fifteen years of public health and
- 0:46Speaker 1: clinical dietetics experience, including serving as a director of the
- 0:50Speaker 1: National School Nutrition Program at the Department of Education. Welcome,
- 0:53Speaker 1: It's great to have you.
- 0:55Speaker 2: Good morning, dear Clarence.
- 0:56Speaker 1: A mouthful.
- 0:58Speaker 2: It is a mouthful. It's such a pleasure to be
- 1:01Speaker 2: a Thanks for having us.
- 1:02Speaker 1: I still get a sense I left some stuff out.
- 1:03Speaker 1: Are the things that I've left? No? Absolutely not okay.
- 1:06Speaker 1: This is a landmark initiative thes SA twenty twenty five
- 1:11Speaker 1: clinical trial. It talks about multiple micronutrient supplementation and I
- 1:17Speaker 1: think it's something that we've spoken about maybe lamented for
- 1:21Speaker 1: too long a period of time in so many spheres.
- 1:25Speaker 1: It's about how just maybe a bull can bring up
- 1:29Speaker 1: the backlog or play the catch up in terms of
- 1:32Speaker 1: your daily nutritional needs. People are not eating properly, and
- 1:37Speaker 1: I think we may just be there. Is that a
- 1:39Speaker 1: suitable introduction or is it too simplistic?
- 1:42Speaker 2: Well, I think that it's a good introduction what's happening currently.
- 1:47Speaker 2: I think we as South Africans are aware that there
- 1:49Speaker 2: is disparity. Some of us don't have access to good
- 1:53Speaker 2: and healthy, nutritious food because it's expensive.
- 1:55Speaker 1: And we're not going to change our habits soon.
- 1:57Speaker 2: Yes, So what it is that MMS brings to the
- 2:01Speaker 2: table is it brings together a level playing field. So
- 2:06Speaker 2: those mothers who are at risk, who are vulnerable, now
- 2:10Speaker 2: have the opportunity to have a supplement that contains fourteen
- 2:14Speaker 2: different micro nutrients to set an environment that will service
- 2:18Speaker 2: the blueprint for their child.
- 2:20Speaker 1: Gotcha. Yeah, So you can have your fries essentially or
- 2:26Speaker 1: your junk food, and the.
- 2:28Speaker 2: Poor absolutely d And we would never advocate for junk
- 2:32Speaker 2: food or fast foods or anything that's been just thrown together.
- 2:37Speaker 2: We would always advocate for a healthy, balanced, and nutritious meal.
- 2:41Speaker 2: But in this context, currently, what's happening in our country
- 2:44Speaker 2: is once a mother goes and informs her health facility
- 2:48Speaker 2: that she is pregnant, she is put on a supplement
- 2:51Speaker 2: to supplements iron and folic acid. And we all know
- 2:54Speaker 2: that's important. The folic acid plays an important role in
- 2:58Speaker 2: the neural development of a child, and the iron is
- 3:01Speaker 2: there to make sure that as this mother's blood plasma
- 3:04Speaker 2: increases to serve this growing baby, there is a need
- 3:08Speaker 2: for additional iron. And so when we have a population
- 3:11Speaker 2: we're about thirty one almost thirty two percent of women
- 3:14Speaker 2: are anemic. We need to address that. And so that's
- 3:17Speaker 2: why the government supplementation programmer is there. But MMS comes
- 3:21Speaker 2: with two decades of experience and it says, not only
- 3:24Speaker 2: do we need the iron and the folic acid, but
- 3:26Speaker 2: we need the thirteen other micro nutrients as well.
- 3:29Speaker 1: I got you, So I think maybe I've extrapolated way
- 3:32Speaker 1: beyond the conversation. So it physiologically empowers the mother to
- 3:38Speaker 1: deliver the healthy baby. And I was thinking about the
- 3:41Speaker 1: baby who's maybe now also going to suffer stunting because
- 3:45Speaker 1: of dietary kind of neese maybe it's a pill that
- 3:47Speaker 1: can be adapted to assist with the needs of a
- 3:50Speaker 1: growing child.
- 3:51Speaker 2: That's one hundred percent correct. And so what we have
- 3:54Speaker 2: currently in the country is about fourteen percent of our
- 3:57Speaker 2: babies that are born, and we have about a million
- 4:00Speaker 2: every financial year. They that fourteen percent is born with
- 4:04Speaker 2: a low birth weight, which means when they're born it's
- 4:06Speaker 2: below they expected two point five kilograms. And from that
- 4:10Speaker 2: we have found that we have a stunting rate, which
- 4:12Speaker 2: is kind of stubborn because we have about twenty seven
- 4:15Speaker 2: percent of stunting, and we know that there is a
- 4:19Speaker 2: developmental delay associated with stunting. So if we want to
- 4:23Speaker 2: have our kids started on an equal footing to pursue
- 4:27Speaker 2: that there we go, take care of their mom, take
- 4:30Speaker 2: care of their community, the society to thrive, we would
- 4:35Speaker 2: want to start at the point of conception.
- 4:37Speaker 1: I got you, okay, yeah, but then take it beyond
- 4:41Speaker 1: births as well.
- 4:42Speaker 2: Well. We have some studies coming out around that, but
- 4:45Speaker 2: for now, the focus.
- 4:47Speaker 1: Is let's celebrate what we have. I'm getting my hopes
- 4:49Speaker 1: out here, but essentially you are looking your objective is
- 4:52Speaker 1: to generate South African clinical evidence. Yes, so we have
- 4:56Speaker 1: do you think that is fair completely. That's done, isn't it.
- 4:59Speaker 2: Yes, at the moment. So we have a great partnership
- 5:02Speaker 2: with the DGMRI Trust and the Vizorhi Consortium, and with
- 5:07Speaker 2: the funding that's been given to us from the Children's
- 5:10Speaker 2: Investment Fund, we have commissioned this project called the MMS
- 5:14Speaker 2: Clinical Trial twenty five twenty six, and so in this
- 5:19Speaker 2: trial we're going to be taking not only the body
- 5:22Speaker 2: of literature that we have for the past two decades
- 5:24Speaker 2: and some experience in the country as well, but we're
- 5:27Speaker 2: also going to monitor these women over a period of
- 5:30Speaker 2: six months and look at the birth outcomes as well
- 5:34Speaker 2: as the adherence and the acceptability of this new supplement
- 5:37Speaker 2: into the system.
- 5:38Speaker 1: Okay, so you are presently in a stage of participant recruitments.
- 5:43Speaker 2: Yes, we are. We've started.
- 5:44Speaker 1: It's going to yes.
- 5:46Speaker 2: So it's taking place in the Region f which is
- 5:49Speaker 2: in the Houting Province, and we have two sites, the
- 5:54Speaker 2: Community Hillbrow Community Health Center and Escellent Clinic. That's where
- 5:59Speaker 2: they are recruiting myn from into our trial. Our population
- 6:02Speaker 2: is seven hundred and ninety five mothers that we would
- 6:05Speaker 2: follow up on two arms, one being the standard of care,
- 6:08Speaker 2: which is iron and folic acid and the other one
- 6:10Speaker 2: being MMS, so to two to one enrollment, So we'll
- 6:13Speaker 2: have about five hundred and thirty mothers on the MMS
- 6:17Speaker 2: for a period of six months.
- 6:18Speaker 1: Okay, So that's where we ask, and I think you
- 6:21Speaker 1: already infer that it's a complete game changer. We're talking
- 6:23Speaker 1: about multiple micronutrient supplementation MMS, a YULIA MMS. It refers
- 6:31Speaker 1: to that and a game changer then compared you mentioned
- 6:35Speaker 1: it compared to traditional ion and folic acid tablets currently
- 6:40Speaker 1: being circulated distributed I would imagine then by hospitals or clinics.
- 6:47Speaker 2: That would be correct.
- 6:48Speaker 1: How does it differ tell us why it's the.
- 6:49Speaker 2: Game So it's the game changer because, as I said,
- 6:52Speaker 2: with iinan pholic acid, you just have two micronutrients that
- 6:56Speaker 2: player pivotal role also in the development of the baby.
- 6:59Speaker 2: But with them you have thirteen additional micro nutrients. So
- 7:04Speaker 2: you've got copper in there, you've got selenium in there,
- 7:06Speaker 2: you've got vitamin AC and E in there, you've got
- 7:08Speaker 2: a range of B vitamins and all of them work
- 7:11Speaker 2: together in the different facets of the child's development, whether
- 7:14Speaker 2: it's their vision whether it is the transportation being done
- 7:19Speaker 2: by the blood in the body, whether it's going to
- 7:22Speaker 2: be the neural development of the child, all of those
- 7:25Speaker 2: works logistically together to give this child an opportunity to
- 7:29Speaker 2: develop and to be born of a healthy birth weight,
- 7:32Speaker 2: and to keep that mother healthy and strong during the
- 7:36Speaker 2: gestational period as well as post delivery.
- 7:39Speaker 1: I would have thought that the World Health Organization, for example,
- 7:42Speaker 1: would have had some kind of some kind of ideas
- 7:45Speaker 1: on this already, some kind of blueprint on it. Why
- 7:48Speaker 1: is it necessary to do this?
- 7:50Speaker 2: So, the World Health Organization has actually put MMS as
- 7:54Speaker 2: part of their Essential Medicine list, so it's already been
- 7:58Speaker 2: flagged there. And this formulation, which is called the UNIMP formulation,
- 8:01Speaker 2: which is this mixture of third or fifteen different micro
- 8:05Speaker 2: nugents was developed by UNSEF. So in South Africa, the
- 8:11Speaker 2: question in the public health space still rides around how
- 8:14Speaker 2: does this find resonance within the South African community. And
- 8:19Speaker 2: with our communication and engagement with the National Department of Health,
- 8:24Speaker 2: they have requested that we have some local studies to
- 8:27Speaker 2: address issues of acceptability and adherence as well. So we
- 8:30Speaker 2: need to contextualize this programming to South Africa because we
- 8:34Speaker 2: are one of the few African countries that actually take
- 8:38Speaker 2: over both the funding and implementations of programming independently.
- 8:44Speaker 1: Okay, So is there any IP in this particular Mmm,
- 8:48Speaker 1: no IP, no formulation.
- 8:50Speaker 2: Now, all of this is freely available information.
- 8:54Speaker 1: Which World Health Organization would have supplied and the pull for.
- 8:58Speaker 2: So it comes in two forms. What we're using at
- 9:00Speaker 2: the moment is a tablet. It can either come in
- 9:04Speaker 2: a container of one hundred and eighty which is with
- 9:07Speaker 2: a six month supply that is recommended, or it can
- 9:10Speaker 2: come in a blaster pack. In South Africa, we're just
- 9:12Speaker 2: using the container with one hundred and eighty tablets at
- 9:14Speaker 2: the moment. But in other countries, I have colleagues in Nigeria,
- 9:19Speaker 2: Indonesia and the Philippines. We're all working on the same
- 9:22Speaker 2: program and they have access to the blaster pack as well.
- 9:26Speaker 2: But because we are just moving into this sort of
- 9:29Speaker 2: developmental space at the moment to help put down the
- 9:32Speaker 2: groundwork for policy and legislative changes, we will get there
- 9:36Speaker 2: within time to see which is it that the women
- 9:39Speaker 2: of South Africa prefer?
- 9:40Speaker 1: Okay, and I have no doubt the child is going
- 9:43Speaker 1: to demonstrate benefits. What is the roadmap thereafter.
- 9:48Speaker 2: So we've actually this program has two phases. Phase one
- 9:52Speaker 2: was about doing the literature re view, doing the value
- 9:55Speaker 2: chain assessment, looking at building a roadmap for South Africa,
- 9:59Speaker 2: and face DO is what we're focusing on now, which
- 10:01Speaker 2: is the clinical study. So we've done some of the
- 10:03Speaker 2: groundwork already. As I said, we've had multiple discussions with
- 10:07Speaker 2: the National Department of Health and they wanted to see
- 10:10Speaker 2: how does one demonstrate not only aspects of the cost
- 10:13Speaker 2: benefit analysis, but also looking at what are the supply
- 10:17Speaker 2: chain logistics mechanisms for costed costs and how it will
- 10:21Speaker 2: impact having this type of intervention in the public policy space.
- 10:27Speaker 1: I don't know if you have stats, because I think
- 10:29Speaker 1: it's such an important conversation that we're having. We're talking
- 10:32Speaker 1: about maternal micronutrient deficiency essentially, and I think you've touched
- 10:37Speaker 1: on fetal neurodevelopment, long term metabolic outcomes in that first
- 10:41Speaker 1: one thousand years. But just stats in terms of how
- 10:45Speaker 1: many children are impacted in South Africa.
- 10:48Speaker 2: Well, yes, we do. As I said to you previously,
- 10:51Speaker 2: about fourteen point two percent of all of our births
- 10:53Speaker 2: in our country. Those children are born at a low
- 10:57Speaker 2: birth weight which means they below the minimum threshold that
- 11:00Speaker 2: one which is two point five kilograms or twenty five
- 11:03Speaker 2: hundred grams pull.
- 11:04Speaker 1: Would necessarily impact weight. Would it?
- 11:06Speaker 2: Absolutely?
- 11:07Speaker 1: At word?
- 11:07Speaker 2: Because if her mother's baseline nutrition is improved and she
- 11:10Speaker 2: continues having access to the micronutrients necessary.
- 11:14Speaker 1: To bowls, WHI still in the home? Right? Okay? Yes? Yes, okay.
- 11:17Speaker 2: So the mother is the carrier of everything that the
- 11:20Speaker 2: child needs in order to be born at a healthy
- 11:24Speaker 2: birth weight.
- 11:25Speaker 1: Child has an equal opportunity at birth absolutely, and the
- 11:29Speaker 1: children Yes, okay, if you put it that way, I'm
- 11:32Speaker 1: even more excited than I was prior to starting this conversation.
- 11:37Speaker 1: Would there be, like any barriers, logistical barriers, other barriers
- 11:40Speaker 1: transitioning South Africa's public health supply chain to MMS. Yes,
- 11:46Speaker 1: absolutely so.
- 11:47Speaker 2: In terms of South Africa, we have a very interesting
- 11:52Speaker 2: combination of urban, pre urban and deeply rural areas. So
- 11:57Speaker 2: when one looks at especially the continueuation of supply, one
- 12:01Speaker 2: make sure that this is equld will access to the intervention.
- 12:05Speaker 2: When we plan for this, we would have to spend
- 12:07Speaker 2: on an ordinate amount of time to sit down and
- 12:10Speaker 2: look at how we can either latch on or improve
- 12:13Speaker 2: the current mechanisms to deliver health care in all of
- 12:17Speaker 2: these environments. If you take especially the big provinces, the
- 12:21Speaker 2: Lions provinces case it in Eastern capel and Properties are
- 12:24Speaker 2: massive provinces but not always having the good road infrastructure
- 12:28Speaker 2: that you need to access that clinic somewhere on the hill.
- 12:31Speaker 2: So when we plan for this, we have to make
- 12:33Speaker 2: sure that we do not exclude mothers and children based
- 12:38Speaker 2: on their location. So we will have to take the
- 12:41Speaker 2: time to make sure that as we work with government,
- 12:44Speaker 2: support government and work with partners, we are able to
- 12:47Speaker 2: overcome that last mile inhibiting factor.
- 12:51Speaker 1: We're not only talking about the distribution of the police
- 12:54Speaker 1: essentially of the MMS. We're talking about convincing traditional kind
- 12:59Speaker 1: of communities, maybe even faith communities around the countries of
- 13:04Speaker 1: the benefits of this particular poll and get a culture
- 13:07Speaker 1: going around it.
- 13:08Speaker 2: Absolutely absolutely, and we know in South Africa there's a
- 13:11Speaker 2: lot of sensitivity, especially in the first trimester of pregnancy,
- 13:15Speaker 2: and it's very important that we engage with stakeholders and
- 13:18Speaker 2: as always, Site and Life looks for local partners. We
- 13:23Speaker 2: look for opportunities to educate and to advocate for the
- 13:26Speaker 2: programs that we implement, so definitely as part of the roadmap.
- 13:30Speaker 2: There also needs to be proper stakeholder engagement, sharing of
- 13:34Speaker 2: good knowledge and information and making sure that mothers have
- 13:38Speaker 2: the opportunity to not only contribute, but take up what
- 13:42Speaker 2: is needed for their baby to have the best start
- 13:44Speaker 2: in life.
- 13:45Speaker 1: Okay, so let's just go to the trial. I would
- 13:47Speaker 1: imagine they are planned clinical kind of visits and that
- 13:51Speaker 1: is a let's call it an environment that you are
- 13:55Speaker 1: are enabling, and it's a controlled environment. That's what I'm
- 13:57Speaker 1: looking for. But outside of that, momy's got to go
- 14:00Speaker 1: home compliance. Is there a degree of compliance that is
- 14:04Speaker 1: required or does mama just continue as is?
- 14:08Speaker 2: So what happens is our mothers are recruited from our
- 14:11Speaker 2: anti natal sites, they come into the trial. Then they're
- 14:15Speaker 2: giving the option to submit their informed consent. Then they
- 14:20Speaker 2: come into the trial environment. It is also located in Hillbrows,
- 14:25Speaker 2: but four minutes from both sides, and there they are screened.
- 14:29Speaker 2: Once mothers are deemed to be eligible for enrollment, they
- 14:34Speaker 2: are then counseled further after looking at the maternity case records,
- 14:40Speaker 2: they are seen by the nursing practitioner. They are prescribed
- 14:44Speaker 2: the arm that they've chosen. Remember I said to you
- 14:46Speaker 2: it's a two to one ratio. So if the mother chooses,
- 14:50Speaker 2: for example, MMS, that's her choice. And then she supplied
- 14:53Speaker 2: with the six months of the MMS. A pharmacist then comes,
- 14:58Speaker 2: so the mother is in one central point and all
- 15:01Speaker 2: the services revolve around. She doesn't need to move anywhere,
- 15:04Speaker 2: just enjoy a cup of tea. When the mother then leaves,
- 15:08Speaker 2: there's a date for scheduled follow ups, which are done telephonically,
- 15:11Speaker 2: and she's given a diary where she needs to write
- 15:14Speaker 2: down whether or not she has adhered to the supplementation schedule,
- 15:18Speaker 2: which is one tablet today not to like iron and
- 15:21Speaker 2: folic acid because those are two separate tablets. And then
- 15:24Speaker 2: there's also in person follow ups. If there are any
- 15:27Speaker 2: adverse events that are reported or any concerns that the
- 15:30Speaker 2: mother may have, she can come directly back to the
- 15:33Speaker 2: trial site. But other than that, she has a standard
- 15:36Speaker 2: routine anti natal care visits at her primary off care provider.
- 15:40Speaker 1: I'm asking if there's an imposition in terms of dietary needs.
- 15:44Speaker 2: Now, absolutely not, absolutely not. There's no dietary requirement that
- 15:49Speaker 2: she would have to adhere to. She continues there we go.
- 15:53Speaker 1: Apart from this pole of day and you know, I'm
- 15:56Speaker 1: post natal again. I would imagine the mother continues with
- 15:58Speaker 1: that regime.
- 16:00Speaker 2: It's not even just post natally. The science and the research,
- 16:04Speaker 2: as discussed at the FIGO last year, the figure conference
- 16:07Speaker 2: in October last year, actually says that one must start
- 16:11Speaker 2: prior to conception. So yes, that's where the rest of
- 16:15Speaker 2: the world is moving already. So in South Africa we're
- 16:19Speaker 2: still trying to just get the gestational period correct, but
- 16:22Speaker 2: others have started prior to conception and continued beyond.
- 16:26Speaker 1: Delivery because the baby. You want the baby to be
- 16:29Speaker 1: dependent on mummy's milk for the next one two three
- 16:32Speaker 1: years and that's going to inform the quality of that supply.
- 16:35Speaker 2: Absolutely exclusive breastfeeding for the first six months of life.
- 16:39Speaker 2: It just makes such a difference to both the mother
- 16:43Speaker 2: and the child. And so if you can support that,
- 16:45Speaker 2: why wouldn't you?
- 16:47Speaker 1: Okay, Now, that makes absolutely a lot of sense. For
- 16:54Speaker 1: people that are let's just say, not dependent on the
- 16:56Speaker 1: public health care system that are able to afford the
- 17:00Speaker 1: best medicine in this country, this wouldn't be a benefit
- 17:05Speaker 1: to them, right or are we there? In terms of
- 17:07Speaker 1: paradigm in terms of MMS in the private sector.
- 17:11Speaker 2: So at the moment, what is happening in the more
- 17:14Speaker 2: privatized healthcare sectors is that there are so many different
- 17:19Speaker 2: products on the shelf, okay, and not all of them
- 17:24Speaker 2: are uniform in their formulation. But what we have inside
- 17:28Speaker 2: MMS is that it is a scientifically backed formulation which
- 17:32Speaker 2: is accepted internationally.
- 17:34Speaker 1: And the brands competing in the private sector.
- 17:36Speaker 2: Yeah so, And also what also sets it slightly apart
- 17:40Speaker 2: is that if you look at the MMS, it contains
- 17:43Speaker 2: thirty milligrams of iron, so thirty milligrams of elemental iron,
- 17:47Speaker 2: whereas your routine supplement that you have on your shelf
- 17:50Speaker 2: is only going to contain about twenty four milligrams of iron.
- 17:54Speaker 2: So once we move through the processes with government and
- 17:57Speaker 2: the registration of this product, it then we available to
- 18:01Speaker 2: everyone in the country. So your privatized obstetrician or guidecologist
- 18:06Speaker 2: is able to prescribe this for you and you are
- 18:08Speaker 2: able to access it and have that for your baby.
- 18:11Speaker 2: But at the moment, there is no product that has
- 18:14Speaker 2: the same formulation as MMS yet.
- 18:17Speaker 1: And I'm just pondering upstream, where's manufacture happening. Is it
- 18:21Speaker 1: South Africa as well?
- 18:22Speaker 2: So we have one manufacturer currently in the country who
- 18:27Speaker 2: exports to other countries whilst we are in the process
- 18:30Speaker 2: of having it registered for use in this country, so.
- 18:34Speaker 1: That means registration has happened in other countries.
- 18:37Speaker 2: A registration this is.
- 18:38Speaker 1: In another African countries?
- 18:39Speaker 2: Are the African countries?
- 18:41Speaker 1: Why do we have to reinvent well.
- 18:44Speaker 2: Because there are certain legal parameters and frameworks that are
- 18:47Speaker 2: there to I suppose keep everybody safe and standardize, and
- 18:51Speaker 2: so there is a process with a healthy regulator to
- 18:55Speaker 2: make sure that we achieve those processes and are as
- 18:58Speaker 2: compliant as possible. It's always good to have a nice
- 19:01Speaker 2: safety mechanism in place so that we can take care
- 19:04Speaker 2: of everyone, including the most vulnerable.
- 19:08Speaker 1: Morning Clarence, I've been talking. I've been taking follic as
- 19:10Speaker 1: acid at the age at age thirty four when I
- 19:13Speaker 1: expected my first baby. I still use it every day
- 19:16Speaker 1: at age seventy three. It makes the hair grow. To
- 19:19Speaker 1: sus Anne, Marie, Okay, that's fantastic, But that's that's that's
- 19:25Speaker 1: just a component.
- 19:26Speaker 2: Of a Yeah, that is just a component of MMS.
- 19:29Speaker 1: But and Marie, I'm going to suggest just I'm going
- 19:33Speaker 1: to propose that some people consider your anecdotal evidence for
- 19:37Speaker 1: hair growth. Some people in the building. Thank you for
- 19:41Speaker 1: your message, and thank you Verona for joining us. It's
- 19:44Speaker 1: been a wonderful conversation on the ground breaking clinical trial
- 19:49Speaker 1: to advance maternal nutrition in South Africa. Verona butt Boy
- 19:53Speaker 1: Site and Life Foundation Country Program South African manager bringing
- 19:56Speaker 1: us up to speed and we appreciate that. Thank you,
- 19:58Speaker 1: Thank you so much. Gre